1 enrolling by invitation. 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 1 | Enrolling by invitation 1 |
Follow Cystic Fibrosis: new trials by email Literature Review of Cystic Fibrosis trials Research Report on Cystic Fibrosis
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Evaluation of Long-Term Safety and Efficacy of Vanzacaftor/Tezacaftor/Deutivacaftor in Cystic Fibrosis Participants 1 Year of Age and Older VNZ/TEZ/D-IVA - Cystic Fibrosis | Phase 3 | Enrolling by invitation | Vertex Pharmaceuticals Incorporated | 174 | 2023-08-11 | 2026-04-29 |
Congenital, Hereditary, and Neonatal Diseases and Abnormalities (1) · Digestive System Diseases (1) · Genetic Diseases, Inborn (1) · Infant, Newborn, Diseases (1) · Lung Diseases (1) · Pancreatic Diseases (1) · Respiratory Tract Diseases (1)
deutivacaftor, tezacaftor , vanzacaftor (1)
Vertex Pharmaceuticals Incorporated (1)
Australia (1) · Canada (1) · France (1) · Germany (1) · Netherlands (1) · New Zealand (1) · Sweden (1) · Switzerland (1) · United Kingdom (1) · United States (1)